MOVIPREP

Moviprep Adverse Events Reported to the FDA Over Time

How are Moviprep adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Moviprep, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Moviprep is flagged as the suspect drug causing the adverse event.

Most Common Moviprep Adverse Events Reported to the FDA

What are the most common Moviprep adverse events reported to the FDA?

Vomiting	40 (3.65%)
Dehydration	27 (2.46%)
Nausea	24 (2.19%)
Convulsion	19 (1.73%)
Hypokalaemia	17 (1.55%)
Diarrhoea	14 (1.28%)
Dyspnoea	14 (1.28%)
Fall	14 (1.28%)
Headache	14 (1.28%)
Dizziness	13 (1.19%)
Hyponatraemia	13 (1.19%)
	Show More
Blood Pressure Increased	12 (1.09%)
Urticaria	12 (1.09%)
Abdominal Pain	11 (1%)
Renal Failure Acute	11 (1%)
Abdominal Distension	10 (.91%)
Drug Hypersensitivity	10 (.91%)
Anaphylactic Shock	9 (.82%)
Atrial Fibrillation	9 (.82%)
Loss Of Consciousness	9 (.82%)
Muscle Spasms	9 (.82%)
Swelling Face	9 (.82%)
Syncope	9 (.82%)
Chills	8 (.73%)
Confusional State	8 (.73%)
Fatigue	8 (.73%)
Hypersensitivity	8 (.73%)
Malaise	8 (.73%)
Pain In Extremity	8 (.73%)
Tremor	8 (.73%)
Anaphylactic Reaction	7 (.64%)
Condition Aggravated	7 (.64%)
Erythema	7 (.64%)
Oedema Peripheral	7 (.64%)
Retching	7 (.64%)
White Blood Cell Count Increased	7 (.64%)
Electrolyte Imbalance	6 (.55%)
Eye Swelling	6 (.55%)
Flatulence	6 (.55%)
Pain	6 (.55%)
Pruritus	6 (.55%)
Blood Chloride Decreased	5 (.46%)
Colitis Ischaemic	5 (.46%)
Disorientation	5 (.46%)
Drug Ineffective	5 (.46%)
Dysgeusia	5 (.46%)
Dysphagia	5 (.46%)
Eructation	5 (.46%)
Gastrooesophageal Reflux Disease	5 (.46%)
Head Injury	5 (.46%)
Insomnia	5 (.46%)
Pallor	5 (.46%)
Paraesthesia	5 (.46%)
Rash	5 (.46%)
Swelling	5 (.46%)
Asthenia	4 (.36%)
Atrial Flutter	4 (.36%)
Blood Glucose Increased	4 (.36%)
Blood Magnesium Decreased	4 (.36%)
Blood Potassium Decreased	4 (.36%)
Bradycardia	4 (.36%)
Cardiac Arrest	4 (.36%)
Cerebral Haemorrhage	4 (.36%)
Chest Discomfort	4 (.36%)
Chest Pain	4 (.36%)
Colitis	4 (.36%)
Conjunctival Haemorrhage	4 (.36%)
Feeling Abnormal	4 (.36%)
Gastrointestinal Sounds Abnormal	4 (.36%)
General Physical Health Deteriorati...	4 (.36%)
Haemoglobin Decreased	4 (.36%)
Irritable Bowel Syndrome	4 (.36%)
Mean Platelet Volume Decreased	4 (.36%)
Presyncope	4 (.36%)
Pyrexia	4 (.36%)
Rash Maculo-papular	4 (.36%)
Swollen Tongue	4 (.36%)
Unresponsive To Stimuli	4 (.36%)
Abortion Spontaneous	3 (.27%)
Accidental Exposure	3 (.27%)
Aggression	3 (.27%)
Angioedema	3 (.27%)
Appendicitis	3 (.27%)
Arrhythmia	3 (.27%)
Blood Calcium Decreased	3 (.27%)
Blood Sodium Decreased	3 (.27%)
Cyanosis	3 (.27%)
Dialysis	3 (.27%)
Disturbance In Attention	3 (.27%)
Drug Effect Decreased	3 (.27%)
Drug Exposure During Pregnancy	3 (.27%)
Drug Interaction	3 (.27%)
Face Oedema	3 (.27%)
Faecal Incontinence	3 (.27%)
Frequent Bowel Movements	3 (.27%)
Gait Disturbance	3 (.27%)
Gout	3 (.27%)
Haematoma	3 (.27%)
Hearing Impaired	3 (.27%)
Hypotension	3 (.27%)
Hypotonia	3 (.27%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Moviprep, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Moviprep is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Moviprep

What are the most common Moviprep adverse events reported to the FDA?

Gastrointestinal Signs	123 (11.22%)
Electrolyte And Fluid Balance Condi...	70 (6.39%)
Neurological	63 (5.75%)
Epidermal And Dermal Conditions	49 (4.47%)
Allergic Conditions	35 (3.19%)
Hematology Investigations	34 (3.1%)
Gastrointestinal Motility And Defec...	33 (3.01%)
Cardiac Arrhythmias	31 (2.83%)
Water, Electrolyte And Mineral	26 (2.37%)
Respiratory	24 (2.19%)
Injuries	22 (2.01%)
	Show More
Infections - Pathogen Unspecified	21 (1.92%)
Seizures	19 (1.73%)
Angiedema And Urticaria	16 (1.46%)
Cardiac And Vascular Investigations	16 (1.46%)
Headaches	16 (1.46%)
Renal Disorders	16 (1.46%)
Deliria	15 (1.37%)
Muscle	15 (1.37%)
Gastrointestinal Inflammatory Condi...	13 (1.19%)
Musculoskeletal And Connective Tiss...	13 (1.19%)
Therapeutic And Nontherapeutic Effe...	13 (1.19%)
Bacterial Infectious	12 (1.09%)
Movement Disorders	11 (1%)
Eye	10 (.91%)
Gastrointestinal Ulceration And Per...	10 (.91%)
Medication Errors	10 (.91%)
Metabolic, Nutritional And Blood Ga...	9 (.82%)
Bone And Joint Injuries	7 (.64%)
Decreased And Nonspecific Blood Pre...	7 (.64%)
Mental Impairment	7 (.64%)
Sleep Disorders	7 (.64%)
Cardiac Disorder Signs	6 (.55%)
Glucose Metabolism Disorders	6 (.55%)
Ocular Hemorrhages And Vascular	6 (.55%)
Ocular Infections, Irritations And ...	6 (.55%)
Oral Soft Tissue Conditions	6 (.55%)
Vascular	6 (.55%)
Acid-base	5 (.46%)
Gastrointestinal Hemorrhages	5 (.46%)
Hearing	5 (.46%)
Hepatobiliary	5 (.46%)
Lifestyle Issues	5 (.46%)
Product Quality Issues	5 (.46%)
Salivary Gland Conditions	5 (.46%)
Vascular Hemorrhagic	5 (.46%)
Vascular Inflammations	5 (.46%)
Anxiety Disorders	4 (.36%)
Body Temperature Conditions	4 (.36%)
Bronchial Disorders	4 (.36%)
Central Nervous System Vascular	4 (.36%)
Embolism And Thrombosis	4 (.36%)
Gastrointestinal Stenosis And Obstr...	4 (.36%)
Hypothalamus And Pituitary Gland	4 (.36%)
Lower Respiratory Tract Disorders	4 (.36%)
Neuromuscular	4 (.36%)
Procedural And Device Related Injur...	4 (.36%)
Psychiatric	4 (.36%)
Renal And Urinary Tract Investigati...	4 (.36%)
Tongue Conditions	4 (.36%)
Vision	4 (.36%)
Abortions And Stillbirth	3 (.27%)
Administration Site Reactions	3 (.27%)
Anemias Nonhemolytic And Marrow Dep...	3 (.27%)
Aural	3 (.27%)
Chemical Injury And Poisoning	3 (.27%)
Coronary Artery	3 (.27%)
Gastrointestinal Conditions	3 (.27%)
Hematological And Lymphoid Tissue T...	3 (.27%)
Personality Disorders	3 (.27%)
Physical Examination Topics	3 (.27%)
Purine And Pyrimidine Metabolism	3 (.27%)
Skin Appendage Conditions	3 (.27%)
Upper Respiratory Tract Disorders	3 (.27%)
Vascular Hypertensive	3 (.27%)
Abdominal Hernias And Other Abdomin...	2 (.18%)
Anal And Rectal Conditions	2 (.18%)
Coagulopathies And Bleeding Diathes...	2 (.18%)
Cranial Nerve Disorders	2 (.18%)
Diverticular	2 (.18%)
Encephalopathies	2 (.18%)
Enzyme	2 (.18%)
Gastrointestinal	2 (.18%)
Gastrointestinal Vascular Condition...	2 (.18%)
Increased Intracranial Pressure And...	2 (.18%)
Ocular Neuromuscular	2 (.18%)
Ocular Sensory Symptoms	2 (.18%)
Pleural	2 (.18%)
Urinary Tract Signs	2 (.18%)
Venous Varices	2 (.18%)
Appetite And General Nutritional	1 (.09%)
Arteriosclerosis, Stenosis, Vascula...	1 (.09%)
Benign Neoplasms Gastrointestinal	1 (.09%)
Bone, Calcium, Magnesium And Phosph...	1 (.09%)
Breast	1 (.09%)
Changes In Physical Activity	1 (.09%)
Depressed Mood Disorders	1 (.09%)
Endocrine Investigations	1 (.09%)
Gastrointestinal Neoplasms Malignan...	1 (.09%)
Gastrointestinal Therapeutic Proced...	1 (.09%)
Heart Failures	1 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Moviprep, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Moviprep is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.